MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2021.01.020

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2021

Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.

Liu Dan, Ma Chunguang, Lu Ping, Gong Jifang, Ye Dingwei, Wang Siyang, Peng Peijian, Bai Yuxian, Song Yuqin, Chen Jianhua, Jiang Ou, Zhang Guojun, Ba Yi, Chen Li, Pan Jianji, Li Qi, Zhang Liling, Gu Shanzhi, Yin Xianli, Cao Bangwei, Han Weiqing, Dong Haiying, Guo Jianming, Zhang Huilai, Su Hang, Jiang Yongsheng, Ouyang Weiwei, Ma Lulin, Sun Yan, Zhang Feng, Lv Jun, Guo Yabing, Xu Chongyuan, Qi Junyuan, Wang Li, Wang Xiang, Liu Zhen, Shen Lin

Клиническое исследование I фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

GLS-010, a novel engineered fully human immunoglobin G4 monoclonal antibody, can specially block the PD-1/PD-L1/2 axis and reactivate the antitumor immunity.

AIM: This phase Ia/Ib study was carried out to evaluate the safety, recommended phase II dose (R2PD), and primary antitumor effects of GLS-010 in patients with advanced, refractory lymphoma and solid tumors.

METHODS

In phase Ia study, patients with refractory solid tumors and lymphoma enrolled and received GLS-010 at a dose of 1, 4, or 10 mg/kg Q2W; 240 mg Q3W or Q2W. The primary objective was to assess the dose-limiting toxicity (DLT). In phase Ib study, doses were expanded in 9 specific tumors to ensure the R2PD and explore the efficacy. Tumor mutation burden level and PD-L1 expression were also assessed with whole-exome sequencing and immunohistochemistry (SP263), respectively.

RESULTS

Up to April 18, 2020, a total of 289 patients (n = 24, phase Ia; n = 265, phase Ib) were enrolled. DLT was not observed in phase Ia part. The T1/2, CLss, and Vd were similar among all dose groups and different tumors. The most common treatment-emergent adverse events (TEAEs) were anemia, leukopenia, elevated alanine aminotransaminase/asparate aminotransferase (ALT/AST), and elevated bilirubin. And hypothyroidism was the most common immune-related adverse event (irAE). The incidence of grade ≥3 TEAE was 39.8%, while grade ≥3 irAE was only 4.5%. Based on safety studies, pharmacokinetics/pharmacodynamics, and preclinical data, 240-mg Q2W was recommended as the expansion dose. The overall objective response rate was 23.6%, with 10 patients achieving complete response. Patients with a high PD-L1 expression level (31.3% Versus. 13.7%, p = 0.012) or t-issue tumor mutation burden level (31.3% Versus. 5.6%, p = 0.009) showed a significantly better response.

CONCLUSION

GLS-010 showed acceptable safety profile and favorable clinical response. The dose of 240 mg Q2W was an optimal recommended dose as monotherapy.

Для цитирования: Liu Dan, Ma Chunguang, Lu Ping, Gong Jifang, Ye Dingwei, Wang Siyang, Peng Peijian, Bai Yuxian, Song Yuqin, Chen Jianhua, Jiang Ou, Zhang Guojun, Ba Yi, Chen Li, Pan Jianji, Li Qi, Zhang Liling, Gu Shanzhi, Yin Xianli, Cao Bangwei, Han Weiqing, Dong Haiying, Guo Jianming, Zhang Huilai, Su Hang, Jiang Yongsheng, Ouyang Weiwei, Ma Lulin, Sun Yan, Zhang Feng, Lv Jun, Guo Yabing, Xu Chongyuan, Qi Junyuan, Wang Li, Wang Xiang, Liu Zhen, Shen Lin. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.. European journal of cancer (Oxford, England : 1990). 2021. DOI: 10.1016/j.ejca.2021.01.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.